✨ Onyx Summary MassBio and SCbio announced the 10 startups selected for this fall’s Drive accelerator, which will run parallel biotech and techbio cohorts to support pre-seed companies tackling challenges in immunology, neuroscience, oncology, AI-driven drug discovery, and more. By equipping founders with mentorship, business tools, and investor
✨ Onyx Summary Seer, Inc. appointed Isaac Ro, Partner at Catalio Capital Management, to its Board of Directors, adding extensive financial and sector expertise in life science tools and diagnostics. Ro’s background in leading high-growth companies through IPOs, acquisitions, and strategic scaling strengthens Seer’s governance as it advances
✨ Onyx Summary Keros Therapeutics announced that CEO Jasbir S. Seehra, Ph.D., will present at the Wells Fargo Healthcare Conference on September 4 and the H.C. Wainwright Global Investment Conference on September 9, 2025. The company will provide corporate and program updates, with presentation replays available for 90 days
✨ Onyx Summary Rocket Pharmaceuticals (NASDAQ: RCKT) will present at the Cantor Fitzgerald and Morgan Stanley Global Healthcare Conferences this September, spotlighting its late-stage genetic therapy pipeline for rare cardiovascular and hematologic disorders. With pivotal programs nearing key milestones, Rocket’s presence underscores its transition toward commercialization—an inflection point
✨ Onyx Summary Guardant Health will host an Investor Day on September 24, 2025, in New York City, offering a deep dive into its leadership’s vision and pipeline—an event that highlights the company’s growing influence in shaping the future of precision oncology. PALO ALTO, Calif.– Guardant Health, Inc.
✨ Onyx Summary Kyverna Therapeutics hosted a virtual KOL event outlining progress in its neuroimmunology CAR T franchise, including updated compassionate use data and details of its FDA-aligned Phase 3 trial design for KYV-101 in myasthenia gravis. The registrational KYSA-6 study, enrolling by year-end 2025, will evaluate
✨ Onyx Summary Lexicon Pharmaceuticals announced that management will participate in fireside chats at Citi’s Biopharma Back to School Conference on September 3, 2025, and the H.C. Wainwright Global Investment Conference on September 8, 2025, with live webcasts available on the company’s investor site. The events provide Lexicon
✨ Onyx Summary Avidity Biosciences announced that its management team will participate in fireside chats at three upcoming investor conferences: the Cantor Global Healthcare Conference (Sept. 3), the Wells Fargo Healthcare Conference (Sept. 4), and the Morgan Stanley Global Healthcare Conference (Sept. 8). The sessions will provide updates on the company’
✨ Onyx Summary Recursion Pharmaceuticals announced participation in two upcoming investor conferences: the Citi 2025 BioPharma Back to School Conference on September 3, 2025, and the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8, 2025. The company’s engagement underscores its strategy to highlight progress in scaling its Recursion
✨ Onyx Summary Belite Bio announced that its executive team will present at three major upcoming investor conferences in early September, including Cantor, Morgan Stanley, and H.C. Wainwright. Each presentation will be webcast and available for replay on the company’s investor relations website. These appearances highlight growing investor interest
✨ Onyx Summary enGene Holdings announced its participation in three upcoming investor conferences in September 2025, including the Wells Fargo Healthcare, H.C. Wainwright Global Investment, and Morgan Stanley Global Healthcare conferences. Management will present company updates and discuss progress on detalimogene voraplasmid, its lead non-viral gene therapy candidate for
✨ Onyx Summary Geron Corporation announced it will participate in a fireside chat at the 2025 Wells Fargo Healthcare Conference in Boston on September 4, 2025, with a live webcast accessible on its investor website. The appearance highlights Geron’s investor engagement strategy as it advances commercialization of RYTELO® and progresses
✨ Onyx Summary Foghorn Therapeutics (Nasdaq: FHTX) announced its participation in three upcoming investor events - Citi’s 2025 Biopharma Back to School Summit, the Wells Fargo Healthcare Conference, and the Morgan Stanley Global Healthcare Conference - where management will engage in one-on-one meetings with investors. The company continues to advance
✨ Onyx Summary Legend Biotech announced that CEO Ying Huang, Ph.D., will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference on September 9, 2025. The event will be webcast live via the company’s investor relations site as Legend continues to expand its CAR-T leadership
✨ Onyx Summary Perspective Therapeutics announced participation in multiple investor conferences in September 2025, including fireside chats and panel discussions at the Cantor Global Healthcare, Morgan Stanley Global Healthcare, and OPCO Targeted Radiopharmaceutical Therapies Summits in New York. The company’s leadership will engage with investors and industry peers to discuss
✨ Onyx Summary MassBio’s 2025 Industry Snapshot revealed the first biopharma job losses in Massachusetts R&D and manufacturing in years, driven by a sharp drop in venture funding, sluggish IPOs, and federal policy uncertainty. Yet with unmatched scientific talent, a dense innovation ecosystem, and renewed state support, the
